MedTrace Logo

A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

NCT00866736 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2015-09-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and the safety of dasatinib in subject with chronic phase chronic myeloid leukemia(CML) who are either resistant to or intolerant of imatinib mesylate.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

dasatinib

100mg QD

Sponsors & Collaborators

  • Epidemiological and Clinical Research Information Network

    collaborator OTHER

  • Kanto CML Study Group

    lead OTHER

Principal Investigators

  • Hisashi Sakamaki, MD.PhD · Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866736 on ClinicalTrials.gov